

AtmosR

Changing patients lives




DEVELOP A TREATMENT FOR CCHS

Xénia Proton de la Chapelle

xenia.proton@atmosr.com

+ 33 6 62 86 90 40

www.atmosr.com




afsonline

AtmosR

Changing patients lives





CCHS CHALLENGES

Ultra rare disease / 2,000 patients

- Big pharmas not interested under € 1b

Both pediatric and adult disease


- Different regulatory routes (PIP)
- Different development (administration, dose...)

Non degenerative disease


- => risk / benefit balance - 200% safety


Need high level of efficiency

- « little improvement » won't work




STEPS AND STAKEHOLDERS IN DRUG DEVELOPMENT







OUR CURRENT ACHIEVEMENTS

450 compounds designed, 35 synthesized, lead ATS-033 identified



Chemoreflexes in isolated CCHS +27Ala mice brainstem





OUR NEXT CHALLENGES

In vivo experiments
and data :
model, administration, dose, frequency...



- Develop our portfolio
- Kennedy disease (10,000)
 - Huntington disease (70,000)



- Engage discussions
with regulatory bodies
- FDA
 - EMA

- Raise money
- \$1,3 mio granted from French government
 - Subject to a fundraising in private equity

